Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. by GUIOT, Julien et al.
RESEARCH ARTICLE Open Access
Raised serum levels of IGFBP-1 and IGFBP-2
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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder of unknown origin, which ultimately
leads to death. Several growth factors such as IGFs (insulin-like-growth factor) and IGFBPs (insulin like growth factor
binding proteins) seem to take part to the pathogenesis. We evaluated IGFs and IGFBPs in serum from patients
with IPF and healthy subjects including 24 untreated IPF and 26 IPF receiving anti-fibrotic therapy and to compare
them with healthy subjects.
Methods: Serum of 50 idiopathic pulmonary fibrosis and 55 healthy subjects (HS) were analysed by ELISA for IGFs
and IGFBPs, TGF-β and KL-6, the latter being tested as positive control in IPF.
Results: Serum levels of IGFBP-1 and IGFBP-2 and KL-6 were significantly higher in the IPF group than in the healthy
subjects (p < 0.05, p < 0.001 and p < 0.0001 respectively) while the picture was inversed regarding IGFs. By contrast
there was no significant difference between the groups with respect to TGF-β. IGFBP-2 was significantly reduced in the
patients with specific anti-fibrotic therapy pirfenidone and nintedanib compared to untreated patients (p < 0.05) but
still significantly elevated in comparison to HS (p < 0.001).
Conclusion: Serum IGFBP-1 and −2 are increased in idiopathic pulmonary fibrosis and IGFBP-2 may be reduced by
anti-fibrosing therapy. IGFBPs may be promising biomarkers in IPF.
Keywords: Idiopathic pulmonary fibrosis, Pulmonary fibrosis, Insuline-like growth factors, Insulin like growth factor
binding proteins
Background
Idiopathic pulmonary fibrosis (IPF) is a complex diagno-
sis and pathology requiring a multidisciplinary approach.
This fibrotic disease has a poor prognosis and requires a
specific and early appropriate therapy [1–3]. In this con-
text several biomarkers (such as surfactant protein A or
SP-A, the Krebs von den Lungen 6 or KL-6, Ig A and
periostin [4–8] were studied without much success to be
discriminant as early diagnostic biomarkers to identify
IPF out of different interstitial lung diseases (ILDs).
Nevertheless when taken together they provided convin-
cing evidence that changes in blood proteins (KL-6, SP-A,
MMP-7, CCL-18, among others) or cells (fibrocytes and
T-cell subpopulations) are indicative in IPF and may
somewhat predict outcome of the disease [9].
The transforming growth factor beta (TGF-β) has long
been known to be involved in the pathophysiology of the
IPF [1]. TGF-β is a stimulus for pulmonary fibrogenesis
by its activity in the control of the remodelling of the
extracellular matrix. TGF-β is also known to be involved
in the fibroblast activity.
Besides TGF-β, there has been recently a growing
interest for the axis IGFs/IGFBPs in fibrosing process. A
recently published study has shown a link between the
production of TGF-β and the production of insulin-like
growth factor binding protein-2 (IGFBP-2) [10] known
to be related to IPF [11] within myofibroblasts cells de-
rived from the lung. Moreover, IGFBP-2 was found at
significantly higher level in the bronchoalveolar lavage of
children with interstitial lung disease [12] relative to
healthy subjects.
IGFBP-2 is also overexpressed in response to a deterior-
ation of the lung parenchyma [13–15]. This overexpression
is mainly perinuclear and proves to be a potential factor of
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fibroblast proliferation [16–19]. The IGFBP-2 protein is
part of a group (IGFBPs) known to be involved in the regu-
lation of insulin-like growth factor (IGF). IGF-1 and IGF-2
play an important role in the growth, differentiation and
cellular metabolism [20, 21]. Signalling pathway of IGF con-
sisted of two isoforms of IGF (−1 and −2), two types of
receptors, six binding proteins with high affinity for IGFs
(IGFBPs) and four binding proteins with low affinity for
IGFs (or related protein IGFBP: IGFBPrp) [11, 22, 23]. The
IGFBPs bind IGFs and can increase their half-life, alter their
function (in potentiating or inhibiting it), or facilitate their
passage to the target tissues [20, 24]. Activity of IGFBP-2 is
controlled on one hand by its secretion and on the other
hand by its proteolysis. Proteolysis of IGFBP-2 is made by
several groups of proteolytic enzymes such as pappalysines,
kallikreins, metalloproteases or the plasmin [25].
There has been recent pharmacological progress in the
treatment of IPF. Drugs such as pirfenidone and ninte-
danib have been shown to slow down the decline in lung
volume that accompanies the lung fibrosing process [2].
We focused our study on the serum measurement of
several growth factors including IGFs and IGFBPs in
order to identify a potential new biomarker in IPF and
sought to determine whether their levels might be influ-
enced by recently developed anti-fibrotic therapy.
Methods
Subject characteristics
We prospectively recruited patients from our ambulatory
care policlinic at CHU Liege and Erasme University
Hospital of Brussels. The patients were divided into 2
groups. The first group was the group of patients with
untreated IPF (n = 24). The second group is a group of
treated IPF patients with a specific therapy (n = 26).
The diagnosis of (definite) IPF was made according to
the international recommendations of the ATS [1]
using the respiratory function test, HRCT scan (prob-
able UIP pattern), bronchoalveolar lavage (when avail-
able), as well as the clinical history of the patient. We
excluded all other causes of interstitial lung disease
(such as asbestosis, hypersensitivity pneumonitis, pneu-
monia associated with connective tissue disease or toxic
pneumonitis). We combined the different results for
the diagnosis. All cases were discussed in a multidiscip-
linary group about interstitial lung diseases composed
of a pulmonologist, a specialist in pulmonary rehabilita-
tion, a rheumatologist, a radiologist, a pathologist and a
specialist in occupational medicine. Sixteen patients
underwent a surgical biopsy and seven patients trans-
bronchial cryobiopsies. Twenty-six patients benefit
from a specific treatment of IPF (pirfenidone (n = 17)
or nintedanib (n = 9)) Fig. 1. We also recruited healthy
subjects by advertisement in our policlinic waiting
room. They all denied any respiratory disease and had
normal spirometric values with FEV1 > 80 % predicted
and FEV1/FVC ratio > 70 %.
The protocol was approved by the ethics committee of
CHU of Liège, and all subjects gave written consent before
their enrollment (Belgian number : B707201422832 ; ref :
2014/302).
Peripheral blood puncture
Venous blood was collected in Vacutainer tubes from an
antecubital site immediately when controls and patients
were included in the study. Blood cell values included
white blood cell count, the differential leukocyte count,
fibrinogen and C-reactive protein (CRP) levels were de-
termined by the routine hospital laboratory.
Biomarkers measurements in serum
We analysed several biomarkers assumed to be critical
growth factors in blood: TGF- β, IGF-1, IGF-2, IGFBP-1,
IGFBP-2 and IGFBP-3 were measured by a specific en-
zyme immunoassay with a commercial kit (TGF-β, IGF-
1, IGFBP-1, IGFBP-2, IGFBP-3: Duoset®, R&D systems,
Minneapolis; IGF-2 : Mediagnost, Reutlingen, Germany;
KL-6 level was measured by a specific enzyme immuno-
assay with a commercial kit (Lumipulse G KL-6 Fujirebio
Europe).
Pulmonary function tests
We performed lung function tests in both routine respira-
tory laboratory of CHU Liège and Erasme University hos-
pital. All spirometric tests performed for this study were
measured using the pneumotachograph JaegerMasterlab
system (Erich Jaeger GmbH, Wuzburg, Germany). The
forced expiratory volume in one second (FEV1) and
forced vital capacity (FVC) were measured in accordance
with the recommendations of the European Respiratory
Society (ERS) [26]. The results were expressed in millilitre
and percent predicted. The Tiffeneau index or FEV1/FVC
was expressed in percent. The total lung capacity (TLC)
was measured by body plethysmography according to
ERS recommendations (Erich Jaeger GmbH, Wuzburg,
Germany). The diffusion capacity of CO (DLCO) and
the report DLCO/AV were measured by the single-breath
carbon monoxide gas transfer method and expressed as
percent predicted (Sensor Medics 2400 He/CO Analyzer
System, Bilthoven, Netherlands).
Statistical analysis
Demographic and functional data were expressed as
mean ± standard deviation (SD). The biomarkers levels
were expressed as median (min-max). When the data
showed normal distribution, they were compared with a
one-way ANOVA, followed by Tukey-Kramer’s post-hoc
testing. When the data did not show a normal distribu-
tion, they were compared with the Kruskal-Wallis test
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followed by Dunn's post-hoc testing. Correlations be-
tween variables were performed using Spearman’s
rank correlation test. A p < 0.05 was considered as
significant.
Results
Subject demographic functional and blood characteristics
The demographic, functional and treatment characteris-
tics of the subjects are given in Table 1. The average age
of IPF patients was slightly higher (74 ± 9 years for un-
treated patients versus 68 ± 9 years for treated patients)
with a male dominance. Spirometric values were moder-
ately lowered and comparable in both the treated and
untreated IPF while DLCO was sharply reduced in both
IPF groups.
There was a significant increase in leukocyte count
of untreated and treated IPF patients (p < 0.0001).
IPF patients also displayed neutrophil (treated IPF :
p < 0.0001; untreated IPF : p < 0.001), monocyte (treated
IPF : p < 0.0001; untreated IPF : p < 0.0001) and eosinophil
counts (treated IPF : p > 0.05; untreated IPF : p < 0.001)
compared to HS (Table 1). By contrast, circulating
lymphocyte count was reduced in untreated IPF compared
to HS. There was an increase in fibrinogen and CRP levels
in untreated IPF compare to HS (Table 1).
Serum growth factors
The results of the serum biochemical markers are listed
in the Table 2. There was a striking increase in IGFBP-1
and −2 in the group of untreated IPF patients compared
to healthy subjects (respectively p < 0.05, p < 0.0001)
(Figs. 2–3), while untreated IPF showed a significant de-
crease in serum IGF-1 (p < 0.05), IGF-2 (p < 0.01) and
IGFBP-3 (p < 0.01). IGFBP-2 levels were lower in those
patients receiving anti-fibrotic therapy but still signifi-
cantly elevated compared to HS (p < 0.001) (Fig. 3).
IGFBP-2 seems to be significantly lowered by specific
IPF therapy irrespective of the molecule used as anti-
fibrotic treatment (median range of 189 (110–231)
ng/ml in the group treated by nintedanib (n = 9) vs
155 (126–192) ng/ml in those receiving pirfenidone
(n = 17), p > 0.05).
Similarly to IGFBP-2, KL-6 was increased in both IPF
groups compared to HS (p < 0.0001) (Fig. 3). By contrast
there was no significant difference between the groups
regarding the levels of TGF-β.
We also calculated the serum molar ratio of IGFs:IGFBPs
known as reflecting the real IGFs activity (Table 2).
Serum ratios of IGF-1:IGFBP-1 (p < 0.01), IGF-1:IGFBP-2
(p < 0.0001), IGF-2:IGFBP-1 (p < 0.05) and IGF-2:IGFBP-2
(p < 0.0001) were significantly lower in the not treated IPF
group than in healthy subjects (Table 2).
Relationship between growth factors and lung function
There was an inverse relationship between spirometric
values and TGF-β in healthy subjects (FVC % pred
R = −0.50, p < 0.05 and FEV1 % pred R = −0.48, p < 0.05)
and untreated IPF (FEV1 % pred R = −0.54, p < 0.05) and
an inverse relationship between IGFBP-1 and DLCO in
treated IPF (R = −0.52, p < 0.05). We didn’t find any correl-
ation between pulmonary function tests and IGFBP-2 and
other biomarkers assessed in our study (Additional file 1:
Table S1).
Discussion
Our study shows for the first time that IPF features a
marked increase in serum IGFBP-1 and IGFBP-2. In
addition IGFBP-2 levels are attenuated in those patients
receiving anti-fibrotic treatment even if the serum
levels remained higher in than those measured in
healthy subjects.
Fig. 1 CONSORT flow chart
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Table 2 Serum biomarkers
Healthy subjects Untreated IPF Treated IPF
IGF-1 (ng/ml) 31 (7–67) 20 (9–102)* 25 (11–57)
IGF-2 (ng/ml) 710 (401–2232) 590 (210–1027)* 586 (282–920)**
IGFBP-1 (ng/ml) 11 (0–180) 22 (4–110)* 9 (1–107)
IGFBP-2 (ng/ml) 94 (34–211) 206 (113–317)*** 153 (32–291)** °
IGFBP-3 (ng/ml) 2132 (1207–4059) 1536 (534–2556)* 2032 (893–3505)
Molar ratio IGF-1 : IGFBP-1 12 (1–314) 3,5 (0,3–36,3)* 9 (1–152)
Molar ratio IGF-1 : IGFBP-2 1,8 (0,2–6,2) 0,4 (0–4,3)*** 0,7 (0,3–5,2)*
Molar ratio IGF-1 : IGFBP-3 0,06 (0,02–0,12) 0,05 (0,03–0,25) 0,05 (0,03–0,1)
Molar ratio IGF-2 : IGFBP-1 247 (20–6735) 110 (11–769)* 259 (20–2429)
Molar ratio IGF-2 : IGFBP-2 40 (10–202) 14 (5–28)*** 19 (7–89)**
Molar ratio IGF-2 : IGFBP-3 1,4 (0,8-5,1) 1,6 (0,6-2,2) 1,2 (0,9-1,8)
TGF-β (ng/ml) 11 (3–21) 11 (5–22) 9 (4–17)
KL-6 (ng/ml) 262 (83–596) 1050 (314–4951)*** 889 (359–6168)***
Data are expressed as median (min-max)
*p < 0.05 **p < 0.001 ***p < 0.0001 compared to healthy subjects
°p < 0.05 °°p < 0.001 °°°p < 0.0001 compared to untreated IPF
Table 1 Patients demographic, functional, treatment and blood characteristics
Healthy subjects n = 55 Untreated IPF n = 24 Treated IPF n = 26
Age, yrs 60 (8) 74 (9)*** 68 (9)***
Gender (M/F) 28/27 19/5 16/3
Height, cm 170 (8) 168 (10) 170 (9)
Weight, Kg 75 (12) 74 (16) 78 (11)
BMI, Kg/m2 26 (3) 26 (4) 27 (3)
Smokers (NS/FS/S) 23/22/6 3/8/6 (6/19/0)
Leucocytes x103/μl 7.00 (5.39) 8.35 (2.35)* 8.42 (2.91)**
Neutrophils (Cell/μl) 3450 (1025) 5614 (2113)*** 5960 (3053)***
Lymphocytes (Cell/μl) 2085 (620) 1676 (825)* 1786 (643)
Monocytes (Cell/μl) 486 (160) 698 (325)** 725 (218)***
Eosinophils (Cell/μl) 173 (125) 314 (266)** 214 (128)
Basophils (Cell/μl) 33 (17) 55 (67) 94 (187)
Fibrinogen (g/l) 3 (0.80) a4 (1.40)*** nd
CRP (mg/l) 1.9 (2.89) a30 (37.89)*** nd
FEV1 post-BD, %pred. 105 (12) 75 (14)*** 67 (13)***
FVC post-BD, %pred. 111 (16) 73 (14)*** 66 (16)***
TLC, %pred. nd 71 (19) 68 (15)
DLCO %pred. nd 37 (11) 38 (13)
KCO %pred. nd 63 (16) 70 (20)
Treatment (pirfenidone/nintedanib) 0/0 0/0 17/9
Pirfenidone (duration of treatment -Month) nd nd 9.9 (7.4)
Nintedanib (duration of treatment -Month) nd nd 14.3 (15.8)
nd not determined
Data are expressed as mean (SD)
Non smoker (NS), former smoker (FS), smoker (S)
*p < 0.05 **p < 0.001 ***p < 0.0001 compared to healthy subjects
an = 13
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Previous studies focusing on IGFBP-2 in fibrosis
showed an increase of IGFBP-2 in the bronchoalveolar
lavage [12] and in the lung tissue of patients with interstitial
lung disease (ILD) without focusing on IPF. IGFBP-2 was
shown to be overexpressed in case of lung epithelial dam-
age [12–15, 27] and its expression was found to be reduced,
together with that of TGF-β, by cyclosporine in vitro [10].
The assay of IGFBP-2 in the serum of patients with idio-
pathic pulmonary fibrosis had never been done before. In
our current study IGFBP-2 was significantly higher in the
serum of patients with IPF compared to healthy subjects.
Of great interest, serum IGFBP-2 decreases with specific
anti-fibrotic treatments without returning to normal values
however. It supports the idea that IGFBP-2 may play a role
in the fibrotic process. As our patients were not treated
with corticoids we can here discard any possible impact of
corticosteroids on IGFBP levels [28].
Reinforcing the potential role of IGFBPs in IPF, IGFBP-1
was also specifically increased, but to a lesser extent, in
IPF compared to HS. The increase of KL-6 in IPF versus
healthy subjects is confirmatory of previous findings
[29, 30] and validates our IPF patient cohort. In sharp
contrast to what we found with IGFBP, serum IGF-1
and −2 were not found to be decreased in IPF in com-
parison to HS which results in a decrease ratio IGF:IGFBP
in patients with IPF. IGFs are very potent growth factors
[20] but, to the best of our knowledge, had not been stud-
ied in human lung fibrosis so far. In an animal model
IGF-1 was shown to stimulate differentiation of fibroblast
into myofibrolast [31], one of the effector of pulmonary
fibrosis [32]. Intuitively we might have expected a dir-
ect relationship between IGFs and disease severity.
However our study didn’t show any correlation between
IGF-:IGFBP ratio and functional impairment including
forced vital capacity and total lung diffusing capacity. The
rise of serum IGFBPs might be seen as a spill over of the
lung fibrotic process since previous studies showed raised
levels in BAL from patients with ILD [12]. How IGFBP
may favour lung fibrosis remains unclear. One potential
explanation is IGFBP-2 can bind to the lung extracellular
matrix [33] and thus can favour the IGF activity by in-
creasing its local availability, which results in an increase
of cellular response to IGF [34]. This trapping mechanism
would explain why IGFs themselves were found to be re-
duced in serum from our patients. Alternatively we cannot
rule out the fact that high IGFBP-2 in IPF may actually re-
flect a protective feed-back mechanism to limit the disease
progression by neutralizing IGFs [35]. On the same line
there is an example where IGFPB-2 is playing a protective
role against anarchic cell proliferation. In non-small cell















































Fig. 3 Serum IGFBP-2 and KL-6 concentrations: Comparison between
treated IPF, untreated IPF and healthy subjects. HS = healthy subjects;












Fig. 2 Serum IGFBP-2 concentration: Comparison between IPF and
healthy subjects. HS = healthy subjects (n = 55); IPF = idiopathic pulmonary
fibrosis (n = 50: treated and untreated)
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and membrane-associated IGFBP-2 competes with IGF
receptors for ligand binding and, thus, are likely to be im-
portant determinants of IGF responsiveness [36]. Interest-
ingly IGF-I and IGFBP-3 are lowered in untreated IPF
patients in comparison to healthy subjects. This decrease
is similar to what it has been shown in ARDS, cystic fibro-
sis and COPD [37]. Moreover these authors suggest that
there may be an inverse association between circulating
levels of IGF-1 and IGFBP-3 and lung compartments
levels where they are upregulated suggesting a different
lung and blood regulation under these circumstances.
In our study serum levels of TGF-β were similar between
the groups confirming the results described by a previous
study [38]. Of course it does not mean that these molecules
did not play a major role within the lung. Indeed TGF-β is
known to take part to the lung fibrosing process and was
shown to be overexpressed in lung tissue of patients with
IPF [39].
Conclusion
We conclude that serum IGFBP-1 and IGFBP-2 are in-
creased in patients with idiopathic pulmonary fibrosis in
comparison to healthy subjects. Moreover, the raised
IGFBP-2 level is attenuated by anti-fibrotic treatment.
The prognostic value of these new biomarkers warrants
further longitudinal studies.
Additional file
Additional file 1: Table S1. Correlations between blood biomarkers
and pulmonary function test. (DOCX 173 kb)
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